Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

This is a Phase 3, randomized, masked, sham-controlled, multicenter study to assess the
safety and efficacy of 4 mg of CLS-TA administered via suprachoroidal injection compared to a
sham injection procedure in the treatment of subjects with macular edema associated with
non-infectious uveitis.

Qualified subjects will be randomized to receive two suprachoroidal injections of CLS-TA
administered to the study eye or two sham injection procedures administered to the study eye
approximately 12 weeks apart (Visit 2 and Visit 5). Follow-up visits will be conducted
monthly up to 24 weeks (Visit 8).

Inclusion Criteria:

- Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)

- Diagnosis of macular edema associated with non-infectious uveitis

- Visual Acuity score of ≥ 5 letters read (20/800 Snellen equivalent) and ≤ 70 letters
read (20/40 Snellen equivalent), in the study eye

Exclusion Criteria:

- Any active ocular disease or infection in the study eye other than uveitis

- Intraocular pressure > 22 mmHg or uncontrolled glaucoma in the study eye

- Any uncontrolled systemic disease that, in the opinion of the Investigator, would
preclude participation in the study